The post screening measures applied to the screen of the MMV Malaria Box identified no compounds that inhibit the Rh5-basigin interaction, whereas the screen of the known drug libraries identified pranlukast as a low micromolar inhibitor of the Rh5 – basigin interaction (Fig. 1). This evidence concerns the gene BSG and malaria.